5. Discussione
5.4 Rilevanza clinica dei ritrovamenti
L’aspetto fondamentale che emerge dal nostro studio è come la riduzione dell’infiammazione, attraverso il trattamento intensivo della parodontite, non si associa ad un miglioramento significativo dello stress ossidativo extracellulare, nonostante nella stessa popolazione si potesse osservare un miglioramento del profilo metabolico che alla funzione endoteliale nel paziente diabetico. Ciò suggerisce che misure delle capacità ossidoreduttive aspecifiche e condotte sul sangue periferico o, più in generale, su liquidi extracellulari, sono di scarsa utilità nel definire il rischio legato all’elevata esposizione allo stress ossidativo nel paziente con DMT2.
115
BIBLIOGRAFIA
1
WHO, Global status report on noncommunicable diseases 2014
2
GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, 2016; 388(10053):1659-1724
3
Ezzati M, Riboli E. Can noncommunicable diseases be prevented? Lessons from studies of populations and individuals. Science 2012;337:1482-1487
4
Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008;100:1672-1694
5
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638
6
Bloom DE, Chisholm D, Jane-Llopis E, Prettner K, Stein A, Feigl A. From burden to “best buys”: reducing the economic impact of non-communicable disease in low- and middle-income countries. Geneva: World Health Organization, 2011
7
David J. Hunter, M.B., B.S., M.P.H., Sc.D. and K. Srinath Reddy, M.D., D.M., noncommunicable diseases, N Engl J Med 2013; 369:1336-1343
8
Paul M. Ridker MD, Brendan M. Everett MD, Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017; 377:1119-1131
9
Ridker MD et al. Effect of IL1beta inibition with canakinumab on incident lung cancer in patients with atherosclerosis: esploratory results from a randomized, double-blind, placebo controlled trial. Lancet, 2017
10
Libby P. Atherosclerosis: disease biology affecting the coronary vasculature. The
American journal of cardiology 2006; 98(12A): 3Q-9Q. 11
Molisse TA, Tunick PA, Kronzon I. Complications of aortic atherosclerosis: atheroemboli and thromboemboli. Current treatment options in cardiovascular
116
12
Miller M. An emerging paradigm in atherosclerosis: focus on subclinical disease.
Postgraduate medicine 2009; 121(2): 49-59 13
Waller BF, Orr CM, Slack JD, Pinkerton CA, Van Tassel J, Peters T. Anatomy, histology, and pathology of coronary arteries: a review relevant to new interventional and imaging techniques--Part IV. Clinical cardiology 1992; 15(9): 675-87.
14
Orekhov AN, Bobryshev YV, Chistiakov DA. The complexity of cell composition of the intima of large arteries: focus on pericyte-like cells. Cardiovascular
research 2014; 103(4): 438-51. 15
Pries AR, Kuebler WM. Normal endothelium. Handbook of experimental
pharmacology 2006; (176 Pt 1): 1-40. 16
Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115(10): 1285-95
17
Quillon A, Fromy B, Debret R. Endothelium microenvironment sensing leading to nitric oxide mediated vasodilation: a review of nervous and biomechanical signals. Nitric oxide : biology and chemistry / official journal of the Nitric Oxide
Society 2015; 45: 20-6 18
Billaud M, Marthan R, Savineau JP, Guibert C. Vascular smooth muscle modulates endothelial control of vasoreactivity via reactive oxygen species production through myoendothelial communications. PloS one 2009; 4(7): e6432
19
Yau JW, Teoh H, Verma S. Endothelial cell control of thrombosis. BMC
cardiovascular disorders 2015; 15(1): 130. 20
Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis.
Circulation research 2007; 100(6): 782-94. 21
Kachamakova-Trojanowska N, Bukowska-Strakova K, Zukowska M, Dulak J, Jozkowicz A. The real face of endothelial progenitor cells - Circulating angiogenic cells as endothelial prognostic marker? Pharmacological reports : PR 2015; 67(4): 793-802.
22
Trepels T, Zeiher AM, Fichtlscherer S. The endothelium and inflammation.
117
23
Ramji DP, Davies TS. Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. Cytokine & growth factor reviews 2015.
24
Touboul PJ. Intima-media thickness of carotid arteries. Frontiers of neurology and
neuroscience 2015; 36: 31-9. 25
Nambi V, Chambless L, He M, et al. Common carotid artery intima-media thickness is as good as carotid intima-media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study. European heart journal 2012; 33(2): 183-90
26
. Moran AE, Tzong KY, Forouzanfar MH, et al. Variations in ischemic heart disease burden by age, country, and income: the Global Burden of Diseases, Injuries, and Risk Factors 2010 study. Global heart 2014; 9(1): 91-9.
27
O'Donnell CJ, Elosua R. [Cardiovascular risk factors. Insights from Framingham Heart Study]. Revista espanola de cardiologia 2008; 61(3): 299-310.
28
Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes care 2003; 26 Suppl 1: S5-20.
29
Ahlqvist E, van Zuydam NR, Groop LC, McCarthy MI. The genetics of diabetic complications. Nature reviews Nephrology 2015; 11(5): 277-87
30
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic medicine : a journal
of the British Diabetic Association 1998; 15(7): 539-53 31
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes care 1997; 20(7): 1183-97
32
WHO Expert Committee on Diabetes Mellitus: second report. World Health
Organization technical report series 1980; 646: 1-80 33
Diabetes mellitus. Report of a WHO Study Group. World Health Organization
118
34
Laakso M, Pyorala K. Age of onset and type of diabetes. Diabetes care 1985; 8(2): 114-7.
35
Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 1997; 46(11): 1701-10.
36
Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science (New
York, NY) 2005; 307(5708): 380-4. 37
Saydah SH, Chandra A, Eberhardt MS. Pregnancy experience among women with and without gestational diabetes in the U.S., 1995 National Survey Of Family Growth. Diabetes care 2005; 28(5): 1035-40
38
Gale EA. The rise of childhood type 1 diabetes in the 20th century. Diabetes 2002; 51(12): 3353-61.
39
Harrison LC, Honeyman MC. Cow's milk and type 1 diabetes: the real debate is about mucosal immune function. Diabetes 1999; 48(8): 1501-7
40
PM, Norris JM, Pallansch MA, Gerling IC, Rewers M. The role of enteroviral infections in the development of IDDM: limitations of current approaches.
Diabetes 1997; 46(2): 161-8 41
Karvonen M, Tuomilehto J, Libman I, LaPorte R. A review of the recent epidemiological data on the worldwide incidence of type 1 (insulin-dependent) diabetes mellitus. World Health Organization DIAMOND Project Group.
Diabetologia 1993; 36(10): 883-92 42
Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. Jama 2001; 286(10): 1195-200.
43
Majno G. The Healing Hand - Man and wound in the ancient world. Cambridge, MA: Harvard University Press; 1975.
44
Majno G, Joris I. Cells, Tissues, and Disease. Second Edition ed. Oxford: Oxford University Press; 2004
45
Tauber AI. Metchnikoff and the phagocytosis theory. Nat Rev Mol Cell Biol 2003; 4(11):897-901.
119
46
Cannon W. Organization for physiological homeostasis. Physiol Rev 1926; 9:399- 431.
47
Nathan C, Ding A. Nonresolving inflammation. Cell 2010; 140(6):871-882
48
Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabet Med 2004; 21(3):203-207
49
Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27(3):813-823
50
Masi Stefano, Leukocyte telomere length, inflammation and age-related diseases. UCL
51
Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity. Physiol Rev 2013; 93(1):1-21
52
Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444(7121):860-867.
53
Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010; 327(5963):291-295
54
Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007; 449(7164):819-826
55
Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev 2009; 227(1):221-233
56
Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5(10):987-995
57
Kabelitz D, Medzhitov R. Innate immunity--cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Curr Opin Immunol 2007; 19(1):1-3
58
Kumar V, Cotran RS, Robbins SL. Robbins Basic Pathology. Saunders; 2003.
59
Medzhitov R, Janeway CA, Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997; 91(3):295-298
60
Krieger M. The other side of scavenger receptors: pattern recognition for host defense. Curr Opin Lipidol 1997; 8(5):275-280.
120
61
Krieger M, Acton S, Ashkenas J, Pearson A, Penman M, Resnick D. Molecular flypaper, host defense, and atherosclerosis. Structure, binding properties, and functions of macrophage scavenger receptors. J Biol Chem 1993; 268(7):4569- 4572.
62
Pearson AM. Scavenger receptors in innate immunity. Curr Opin Immunol 1996; 8(1):20-28.
63
Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A. The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med 1998; 187(12):2097-2101
64
Faure E, Equils O, Sieling PA, Thomas L, Zhang FX, Kirschning CJ et al. Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem 2000; 275(15):11058-11063
65
Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001; 13(2):85-94
66
Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007; 7(10):803-815
67
Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006; 6(3):173-182
68
Perry AK, Chen G, Zheng D, Tang H, Cheng G. The host type I interferon response to viral and bacterial infections. Cell Res 2005; 15(6):407-422
69
Mitre E, Taylor RT, Kubofcik J, Nutman TB. Parasite antigen-driven basophils are a major source of IL-4 in human filarial infections. J Immunol 2004; 172(4):2439- 2445
70
Sokol CL, Barton GM, Farr AG, Medzhitov R. A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat Immunol 2008; 9(3):310-318.
71
Luttikhuizen DT, Harmsen MC, van Luyn MJ. Cellular and molecular dynamics in the foreign body reaction. Tissue Eng 2006; 12(7):1955-1970
121
72
Rock KL, Kono H. The inflammatory response to cell death. Annu Rev Pathol 2008; 3:99-126.
73
Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81(1):1-5
74
Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440(7081):228-232
75
Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006; 290(3):C917-C924
76
Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97(7):889-901
77
Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007; 21(2):325-332.
78
Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, Haslett C. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 1989; 83(3):865-875.
79
Savill JS, Henson PM, Haslett C. Phagocytosis of aged human neutrophils by macrophages is mediated by a novel "charge-sensitive" recognition mechanism. J Clin Invest 1989; 84(5):1518-1527
80
Strieter RM, Gomperts BN, Keane MP. The role of CXC chemokines in pulmonary fibrosis. J Clin Invest 2007; 117(3):549-556
81
Libby P. Inflammation in atherosclerosis. Nature 2002; 420(6917):868-874
82
Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6(7):508-519
83
122
84
Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007; 7(2):161-167
85
Schenten D, Medzhitov R. The control of adaptive immune responses by the innate immune system. Adv Immunol 2011; 109:87-124.
86
Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449(7161):419-426
87
Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 2008; 8(12):935-947.
88
Reis e Sousa. Dendritic cells in a mature age. Nat Rev Immunol 2006; 6(6):476- 483
89
Sallusto F, Lanzavecchia A. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev 2000; 177:134-140
90
Wykes M, MacPherson G. Dendritic cell-B-cell interaction: dendritic cells provide B cells with CD40-independent proliferation signals and CD40-dependent survival signals. Immunology 2000; 100(1):1-3
91
Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000; 1(3):199-205.
92
Rautajoki KJ, Kylaniemi MK, Raghav SK, Rao K, Lahesmaa R. An insight into molecular mechanisms of human T helper cell differentiation. Ann Med 2008; 40(5):322-335.
93
Masi Stefano, Leukocyte telomere length, inflammation and age related diseases, UCL
94
Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 2010; 28:445-489
95
Drayton DL, Liao S, Mounzer RH, Ruddle NH. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol 2006; 7(4):344-353
96
Busso N, Ea HK. The mechanisms of inflammation in gout and pseudogout (CPP- induced arthritis). Reumatismo 2011; 63(4):230-237
123
97
Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 2003; 3(9):578- 590
98
Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318(20):1315-1321
99
Yan SF, Barile GR, D'Agati V, Du YS, Ramasamy R, Schmidt AM. The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications. Curr Diab Rep 2007; 7(2):146-153
100
Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005; 11(11):1173-1179.
101
Ershler WB. Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc 1993; 41(2):176-181.
102
Wei J, Xu H, Davies JL, Hemmings GP. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci 1992; 51(25):1953-1956
103
Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhoj P, Pedersen BK. A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci 1999; 54(7):M357-M364
104
Hager K, Machein U, Krieger S, Platt D, Seefried G, Bauer J. Interleukin-6 and selected plasma proteins in healthy persons of different ages. Neurobiol Aging 1994; 15(6):771-772
105
Di IA, Ferrucci L, Sparvieri E, Cherubini A, Volpato S, Corsi A et al. Serum IL- 1beta levels in health and disease: a population-based study. 'The InCHIANTI study'. Cytokine 2003; 22(6):198-205.
106
Ferrucci L, Harris TB, Guralnik JM, Tracy RP, Corti MC, Cohen HJ et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 1999; 47(6):639-646
107
Fagiolo U, Cossarizza A, Scala E, Fanales-Belasio E, Ortolani C, Cozzi E et al. Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol 1993; 23(9):2375-2378
124
108
Cohen HJ, Pieper CF, Harris T, Rao KM, Currie MS. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol A Biol Sci Med Sci 1997; 52(4):M201-M208
109
Kanapuru B, Ershler WB. Inflammation, coagulation, and the pathway to frailty. Am J Med 2009; 122(7):605-613
110
Fried LP, Xue QL, Cappola AR, Ferrucci L, Chaves P, Varadhan R et al. Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. J Gerontol A Biol Sci Med Sci 2009; 64(10):1049-1057
111
Fulop T, Larbi A, Witkowski JM, McElhaney J, Loeb M, Mitnitski A et al. Aging, frailty and age-related diseases. Biogerontology 2010; 11(5):547-563
112
Franceschi C, Monti D, Sansoni P, Cossarizza A. The immunology of exceptional individuals: the lesson of centenarians. Immunol Today 1995; 16(1):12-16
113
Larbi A, Franceschi C, Mazzatti D, Solana R, Wikby A, Pawelec G. Aging of the immune system as a prognostic factor for human longevity. Physiology (Bethesda ) 2008; 23:64-74
114
Franceschi C, Bonafe M, Valensin S, Olivieri F, De LM, Ottaviani E et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000; 908:244-254.
115
Kovacs EJ, Palmer JL, Fortin CF, Fulop T, Jr., Goldstein DR, Linton PJ. Aging and innate immunity in the mouse: impact of intrinsic and extrinsic factors. Trends Immunol 2009; 30(7):319-324.
116
Brod SA. Unregulated inflammation shortens human functional longevity. Inflamm Res 2000; 49(11):561-570
117
Lykkesfeldt J, Hagen TM, Vinarsky V, Ames BN. Age-associated decline in ascorbic acid concentration, recycling, and biosynthesis in rat hepatocytes-- reversal with (R)-alpha-lipoic acid supplementation. FASEB J 1998; 12(12):1183- 1189
118
Filomeni G, Rotilio G, Ciriolo MR. Cell signalling and the glutathione redox system. Biochem Pharmacol 2002; 64(5-6):1057-1064.
125
119
Boveris A, Chance B. The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem J 1973; 134(3):707- 716
120
Cho CG, Kim HJ, Chung SW, Jung KJ, Shim KH, Yu BP et al. Modulation of glutathione and thioredoxin systems by calorie restriction during the aging process. Exp Gerontol 2003; 38(5):539-548.
121
Salminen A, Ojala J, Kaarniranta K, Kauppinen A. Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age- related diseases. Cell Mol Life Sci 2012; 69(18):2999-3013
122
Wong-Ekkabut J, Xu Z, Triampo W, Tang IM, Tieleman DP, Monticelli L. Effect of lipid peroxidation on the properties of lipid bilayers: a molecular dynamics study. Biophys J 2007; 93(12):4225-4236
123
Stadtman ER. The status of oxidatively modified proteins as a marker of aging. In: Esser K, Martin GM, editors. Molecular Aspects of Aging. Chichester: Wiley; 1995. 129-144.
124
Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A 1993; 90(17):7915- 7922
125
Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956; 11(3):298-300
126
Stadtman ER. Protein oxidation and aging. Science 1992; 257(5074):1220-1224.
127
Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 2011; 208(3):519-533
128
Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 2011; 12(3):222-230.
126
129
Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011; 469(7329):221-225
130
Ding WX, Yin XM. Mitophagy: mechanisms, pathophysiological roles, and analysis. Biol Chem 2012; 393(7):547-564.
131
He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 2009; 43:67-93
132
Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell 2010; 40(2):280-293
133
Lipinski MM, Zheng B, Lu T, Yan Z, Py BF, Ng A et al. Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease. Proc Natl Acad Sci U S A 2010; 107(32):14164-14169.
134
Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol 2011; 12(1):9-14.
135
Wong E, Cuervo AM. Autophagy gone awry in neurodegenerative diseases. Nat Neurosci 2010; 13(7):805-811.
136
Gustafsson AB, Gottlieb RA. Autophagy in ischemic heart disease. Circ Res 2009; 104(2):150-158.
137
Gottlieb RA, Mentzer RM. Autophagy during cardiac stress: joys and frustrations of autophagy. Annu Rev Physiol 2010; 72:45-59
138
Madeo F, Tavernarakis N, Kroemer G. Can autophagy promote longevity? Nat Cell Biol 2010; 12(9):842-846
139
Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132(1):27-42
140
Zhou R, Yazdi AS, Menu P, A role for mithocondria in NLP3inflammosome activation. Nature, 2010
141
Nakahira K, Haspel JA, Rathinam VA, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 2010; 12:222-230
142
127
143
Andreasen AS, Krabbe KS, Krogh-Madsen R, Taudorf S, Pedersen BK, Moller K. Human endotoxemia as a model of systemic inflammation. Current medicinal
chemistry 2008; 15(17): 1697-705. 144
Pinero-Lambea C, Ruano-Gallego D, Fernandez LA. Engineered bacteria as therapeutic agents. Current opinion in biotechnology 2015; 35: 94-102
145
Medzhitov R, Janeway C, Jr. Innate immunity. The New England journal of
medicine 2000; 343(5): 338-44. 146
Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. Journal of immunology (Baltimore, Md :
1950) 1995; 155(10): 5038-45 147
Suffredini AF, Hochstein HD, McMahon FG. Dose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. The Journal of infectious diseases 1999; 179(5): 1278-82.
148
Krogh-Madsen R, Moller K, Dela F, Kronborg G, Jauffred S, Pedersen BK. Effect of hyperglycemia and hyperinsulinemia on the response of IL-6, TNF-alpha, and FFAs to low-dose endotoxemia in humans. American journal of physiology
Endocrinology and metabolism 2004; 286(5): E766-72. 149
Barber AE, Coyle SM, Fischer E, et al. Influence of hypercortisolemia on soluble tumor necrosis factor receptor II and interleukin-1 receptor antagonist responses to endotoxin in human beings. Surgery 1995; 118(2): 406-10; discussion 10-1.
150
van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76(12): 2520-6.
151
Granowitz EV, Santos AA, Poutsiaka DD, et al. Production of interleukin-1- receptor antagonist during experimental endotoxaemia. Lancet (London, England) 1991; 338(8780): 1423-4.
152
Van Eijk LT, Dorresteijn MJ, Smits P, van der Hoeven JG, Netea MG, Pickkers P. Gender differences in the innate immune response and vascular reactivity
128
following the administration of endotoxin to human volunteers. Critical care
medicine 2007; 35(6): 1464-9 153
Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJ, van der Poll T. Proinflammatory effects of IL-10 during human endotoxemia. Journal of
immunology (Baltimore, Md : 1950) 2000; 165(5): 2783-9 154
Bornstein SR, Wolkersdorfer GW, Tauchnitz R, Preas HL, 2nd, Chrousos GP, Suffredini AF. Plasma dehydroepiandrosterone levels during experimental endotoxemia and anti-inflammatory therapy in humans. Critical care medicine 2000; 28(6): 2103-6.
155
Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330(6149): 662-4. 286
156
Michie HR, Spriggs DR, Manogue KR, et al. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 1988; 104(2): 280-6.
157
Steensberg A, Fischer CP, Sacchetti M, et al. Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. The Journal of physiology 2003; 548(Pt 2): 631-8.
158
Hingorani AD, Cross J, Kharbanda RK, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000; 102(9): 994-9.
159
Kharbanda RK, Walton B, Allen M, et al. Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation